Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Brinda Alagesan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7085-0260; OpenAlex author ID A5070736447, A5109602571; NIH RePORTER profile ID 12507059. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
67
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 2 papers, 1 grant · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  2. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Co-author DOI 10.1073/pnas.2016904118↗
  3. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  4. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  5. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-18-1409↗
  6. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  7. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1591↗
  8. TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Co-author DOI 10.1158/0008-5472.can-12-0634↗

Grants 1

  1. Role of Nix in pancreatic ductal adenocarcinoma F30CA200240↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Youngkyu Park · 5 shared papers, 2015–2021 · strength 0.37
  2. David Arthur Tuveson · 5 shared papers, 2015–2021 · strength 0.37
  3. Kenneth H. Yu · 3 shared papers, 2015–2026 · strength 0.31
  4. Tobiloba E. Oni · 3 shared papers, 2015–2021 · strength 0.22
  5. Milind M. Javle · 1 shared paper, 2026 · strength 0.22
  6. Anna M. Varghese · 1 shared paper, 2026 · strength 0.22
  7. Talia Golan · 1 shared paper, 2026 · strength 0.22
  8. Celina Ang · 1 shared paper, 2026 · strength 0.22
  9. Wungki Park · 1 shared paper, 2026 · strength 0.22
  10. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.22
  11. Manoop S. Bhutani · 1 shared paper, 2026 · strength 0.22
  12. Mark Andrew Schattner · 1 shared paper, 2026 · strength 0.22
  13. Ralph H. Hruban · 3 shared papers, 2015–2020 · strength 0.17
  14. Hervé Tiriac · 3 shared papers, 2015–2020 · strength 0.17
  15. Linda Van Aelst · 1 shared paper, 2021 · strength 0.12
  16. Derek K. Cheng · 1 shared paper, 2021 · strength 0.12
  17. Jennifer Susan Thalappillil · 1 shared paper, 2021 · strength 0.12
  18. Lindsey A. Baker · 2 shared papers, 2015–2020 · strength 0.11
  19. Chang‐Il Hwang · 2 shared papers, 2015–2020 · strength 0.11
  20. Dannielle D. Engle · 2 shared papers, 2015–2019 · strength 0.10
  21. Christopher R. Vakoc · 1 shared paper, 2020 · strength 0.08
  22. Benno Traub · 1 shared paper, 2020 · strength 0.08
  23. Giuseppina Caligiuri · 1 shared paper, 2020 · strength 0.08
  24. Koji Miyabayashi · 1 shared paper, 2020 · strength 0.08
  25. Tim D.D. Somerville · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.